-
Something wrong with this record ?
Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA)
F. Iannone, DS. Courvoisier, JE. Gottenberg, MV. Hernandez, E. Lie, H. Canhão, K. Pavelka, ML. Hetland, C. Turesson, X. Mariette, D. Choquette, A. Finckh,
Language English Country Germany
Document type Journal Article, Multicenter Study
NLK
ProQuest Central
from 1997-01-01 to 2017-12-31
Medline Complete (EBSCOhost)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-01-01 to 2017-12-31
- MeSH
- Abatacept administration & dosage adverse effects MeSH
- Antirheumatic Agents administration & dosage adverse effects MeSH
- Adult MeSH
- Body Mass Index * MeSH
- Remission Induction MeSH
- Kaplan-Meier Estimate MeSH
- Middle Aged MeSH
- Humans MeSH
- Multivariate Analysis MeSH
- Proportional Hazards Models MeSH
- Prospective Studies MeSH
- Registries MeSH
- Arthritis, Rheumatoid drug therapy MeSH
- Rheumatoid Factor blood MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Geographicals
- Europe MeSH
Some evidences suggest that obesity impairs the effectiveness of TNF inhibitors. We examined the impact of body mass index (BMI) on the clinical effectiveness of abatacept in rheumatoid arthritis (RA) patients. This is a pooled analysis of 10 prospective cohorts of RA patients. All patients with available BMI were included in this study. The primary endpoint was drug retention of abatacept in the different BMI categories. Multivariable Cox regression was used to estimate hazard ratios (HRs) for drug discontinuation. A secondary endpoint was EULAR/LUNDEX response rates at 6/12 months. Of the 2015 RA patients initiating therapy with IV abatacept, 380 (18.9%) were classified as obese. Obese patients had more functional disability, and were less often RF positive. The median abatacept retention time was 1.91 years for obese RA patients compared to 2.12 years for non-obese patients (p = 0.15). The risk of abatacept discontinuation was not significantly different for overweight (HR 1.03 (95% CI 0.89-1.19)), or for obese (HR 1.08 (95% CI 0.89-1.30)) compared to normal-weight patients. Rheumatoid factor positivity reduced the risk of abatacept discontinuation (HR 0.83 (95% CI 0.72-0.95)), while previous biologic therapy was positively associated with drug interruption (HRs increasing from 1.68 to 2.16 with the line of treatments). Obese and non-obese patients attained similar rates of EULAR/LUNDEX clinical response at 6/12 months. Drug retention and clinical response rates to abatacept do not seem to be decreased by obesity in RA patients.
Diakonhjemmet Hospital Oslo Norway
Institut of Rheumatology of Montreal CHUM Montreal Canada
Lund University Malmö Sweden Skåne University Hospital Malmö Sweden
Reuma pt Santa Maria Hospital Lisbon Portugal
Rheumatology Department Hospital Clínic of Barcelona Barcelona Spain
University Hospital Geneva Switzerland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031220
- 003
- CZ-PrNML
- 005
- 20171101101810.0
- 007
- ta
- 008
- 171025s2017 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10067-016-3505-5 $2 doi
- 035 __
- $a (PubMed)27966068
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Iannone, Florenzo $u Department of Emergency and Organ Trasplantation-Rheumatology Unit, University of Bari, Policlinico, Piazza G. Cesare 11, 70124, Bari, Italy. florenzo.iannone@uniba.it.
- 245 10
- $a Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA) / $c F. Iannone, DS. Courvoisier, JE. Gottenberg, MV. Hernandez, E. Lie, H. Canhão, K. Pavelka, ML. Hetland, C. Turesson, X. Mariette, D. Choquette, A. Finckh,
- 520 9_
- $a Some evidences suggest that obesity impairs the effectiveness of TNF inhibitors. We examined the impact of body mass index (BMI) on the clinical effectiveness of abatacept in rheumatoid arthritis (RA) patients. This is a pooled analysis of 10 prospective cohorts of RA patients. All patients with available BMI were included in this study. The primary endpoint was drug retention of abatacept in the different BMI categories. Multivariable Cox regression was used to estimate hazard ratios (HRs) for drug discontinuation. A secondary endpoint was EULAR/LUNDEX response rates at 6/12 months. Of the 2015 RA patients initiating therapy with IV abatacept, 380 (18.9%) were classified as obese. Obese patients had more functional disability, and were less often RF positive. The median abatacept retention time was 1.91 years for obese RA patients compared to 2.12 years for non-obese patients (p = 0.15). The risk of abatacept discontinuation was not significantly different for overweight (HR 1.03 (95% CI 0.89-1.19)), or for obese (HR 1.08 (95% CI 0.89-1.30)) compared to normal-weight patients. Rheumatoid factor positivity reduced the risk of abatacept discontinuation (HR 0.83 (95% CI 0.72-0.95)), while previous biologic therapy was positively associated with drug interruption (HRs increasing from 1.68 to 2.16 with the line of treatments). Obese and non-obese patients attained similar rates of EULAR/LUNDEX clinical response at 6/12 months. Drug retention and clinical response rates to abatacept do not seem to be decreased by obesity in RA patients.
- 650 _2
- $a abatacept $x aplikace a dávkování $x škodlivé účinky $7 D000069594
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antirevmatika $x aplikace a dávkování $x škodlivé účinky $7 D018501
- 650 _2
- $a revmatoidní artritida $x farmakoterapie $7 D001172
- 650 12
- $a index tělesné hmotnosti $7 D015992
- 650 _2
- $a Evropa $7 D005060
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a multivariační analýza $7 D015999
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a revmatoidní faktor $x krev $7 D012217
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Courvoisier, Delphine S $u University Hospital, Geneva, Switzerland.
- 700 1_
- $a Gottenberg, Jacques Eric $u University Hospital, Strasbourg, France.
- 700 1_
- $a Hernandez, Maria Victoria $u Rheumatology Department Hospital Clínic of Barcelona, Barcelona, Spain.
- 700 1_
- $a Lie, Elisabeth $u Diakonhjemmet Hospital, Oslo, Norway.
- 700 1_
- $a Canhão, Helena $u Reuma.pt, Santa Maria Hospital, Lisbon, Portugal.
- 700 1_
- $a Pavelka, Karel $u University Hospital, Prague, Czech Republic.
- 700 1_
- $a Hetland, Merete Lund $u DANBIO and COPECARE, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- 700 1_
- $a Turesson, Carl $u Lund University, Malmö, Sweden. Skåne University Hospital, Malmö, Sweden.
- 700 1_
- $a Mariette, Xavier $u Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, INSERM U1012, Université Paris-Sud, Le Kremlin Bicêtre, France.
- 700 1_
- $a Choquette, Denis $u Institut of Rheumatology of Montreal, CHUM, Montreal, Canada.
- 700 1_
- $a Finckh, Axel $u University Hospital, Geneva, Switzerland.
- 773 0_
- $w MED00001162 $t Clinical rheumatology $x 1434-9949 $g Roč. 36, č. 4 (2017), s. 773-779
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27966068 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171101101901 $b ABA008
- 999 __
- $a ok $b bmc $g 1254813 $s 992247
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 36 $c 4 $d 773-779 $e 20161214 $i 1434-9949 $m Clinical rheumatology $n Clin Rheumatol $x MED00001162
- LZP __
- $a Pubmed-20171025
